Abstract
Inflammatory bowel diseases [IBD], ulcerative colitis [UC] and Crohn ’ s disease [CD], are chronic intestinal disorders of unknown etiology. UC and CD are heterogeneous diseases characterized by various genetic abnormalities that lead to overly aggressive T-cell responses to a subset of commensal enteric bacteria in genetically susceptible individuals. As one of critical factors involved in pathogenesis of IBD, relative imbalance of aggressive and protective bacterial species, termed dysbiosis, has been reported by various literatures. Since early days of microbiology, representatives of microbial species [over 400 species] have been isolated from human gastrointestinal tract, and analyses of dysbiosis in IBD were mainly dependent on culture techniques. However, recent molecular ecological studies based on ribosomal RNA [rRNA] sequences have revealed that cultivation has been able only to access a small fraction of the microbial diversity within the gastrointestinal tract. These techniques enable characterization and quantification of the microbiota. Clone libraries enable identification of the composition of the microbiota. Microbial community structure can be analyzed via fingerprinting techniques, and dot blot hybridization or fluorescent in situ hybridization can analyze abundance of particular taxa. Recent report shows a systematic framework of the microbial diversity in the human gut of more than 1000 different species-level phylogenetic types [phylotypes]. This review focuses on recent advances in the molecular ecological approaches for studying the gut microbiota in IBD.
Current Pharmaceutical Design
Title: Recent Advances in Molecular Approaches to Gut Microbiota in Inflammatory Bowel Disease
Volume: 15 Issue: 18
Author(s): Akira Andoh, Yoshimi Benno, Osamu Kanauchi and Yoshihide Fujiyama
Affiliation:
Abstract: Inflammatory bowel diseases [IBD], ulcerative colitis [UC] and Crohn ’ s disease [CD], are chronic intestinal disorders of unknown etiology. UC and CD are heterogeneous diseases characterized by various genetic abnormalities that lead to overly aggressive T-cell responses to a subset of commensal enteric bacteria in genetically susceptible individuals. As one of critical factors involved in pathogenesis of IBD, relative imbalance of aggressive and protective bacterial species, termed dysbiosis, has been reported by various literatures. Since early days of microbiology, representatives of microbial species [over 400 species] have been isolated from human gastrointestinal tract, and analyses of dysbiosis in IBD were mainly dependent on culture techniques. However, recent molecular ecological studies based on ribosomal RNA [rRNA] sequences have revealed that cultivation has been able only to access a small fraction of the microbial diversity within the gastrointestinal tract. These techniques enable characterization and quantification of the microbiota. Clone libraries enable identification of the composition of the microbiota. Microbial community structure can be analyzed via fingerprinting techniques, and dot blot hybridization or fluorescent in situ hybridization can analyze abundance of particular taxa. Recent report shows a systematic framework of the microbial diversity in the human gut of more than 1000 different species-level phylogenetic types [phylotypes]. This review focuses on recent advances in the molecular ecological approaches for studying the gut microbiota in IBD.
Export Options
About this article
Cite this article as:
Andoh Akira, Benno Yoshimi, Kanauchi Osamu and Fujiyama Yoshihide, Recent Advances in Molecular Approaches to Gut Microbiota in Inflammatory Bowel Disease, Current Pharmaceutical Design 2009; 15 (18) . https://dx.doi.org/10.2174/138161209788489186
DOI https://dx.doi.org/10.2174/138161209788489186 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Purinergic Receptors and Pain
Current Pharmaceutical Design Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Micro Composite Palmitoylethanolamide/Rutin Reduces Vascular Injury through Modulation of the Nrf2/HO−1 and NF-kB Pathways
Current Medicinal Chemistry Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
Current Medicinal Chemistry Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) The Diagnostic Challenge of Appendicitis in Infancy
Current Pediatric Reviews Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Lymphatics and Inflammation
Current Medicinal Chemistry Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry MK-0626, A Dipeptidyl Peptidase-4 Inhibitor, Improves Neovascularization by Increasing Both the Number of Circulating Endothelial Progenitor Cells and Endothelial Nitric Oxide Synthetase Expression
Current Medicinal Chemistry Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology